Zosano Pharma (NASDAQ:ZSAN) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Zosano Pharma (NASDAQ:ZSAN) from a sell rating to a hold rating in a report released on Saturday, Zacks.com reports.

According to Zacks, “Zosano Pharma Corporation is a biopharmaceutical company. It is engaged in developing a transdermal micro needle patch system to deliver formulations of existing drugs through the skin for the treatment of a variety of indications. The Company’s lead product candidates include Weekly ZP-PTH for severe osteoporosis; ZP-Glucagon for severe hypoglycemia and ZP-Triptan, for migraine. Zosano Pharma Corporation is headquartered in Fremont, California. “

A number of other analysts also recently commented on the stock. ValuEngine upgraded shares of Zosano Pharma from a hold rating to a buy rating in a research report on Thursday, April 2nd. Maxim Group restated a buy rating on shares of Zosano Pharma in a research report on Wednesday, May 20th. HC Wainwright restated a buy rating and set a $4.00 price target on shares of Zosano Pharma in a research report on Monday, June 15th. Finally, BTIG Research lowered their price objective on shares of Zosano Pharma from $16.00 to $7.00 and set a buy rating on the stock in a research note on Friday, March 27th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $4.00.

Shares of NASDAQ:ZSAN opened at $0.82 on Friday. Zosano Pharma has a fifty-two week low of $0.41 and a fifty-two week high of $3.54. The company has a market cap of $44.18 million, a PE ratio of -0.45 and a beta of 2.73. The company’s 50-day moving average price is $0.90 and its 200 day moving average price is $0.94. The company has a quick ratio of 0.93, a current ratio of 0.93 and a debt-to-equity ratio of 0.23.

Zosano Pharma (NASDAQ:ZSAN) last released its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. As a group, equities analysts anticipate that Zosano Pharma will post -0.5 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in ZSAN. Ieq Capital LLC acquired a new position in shares of Zosano Pharma in the 4th quarter worth approximately $79,000. Oxford Asset Management LLP purchased a new position in shares of Zosano Pharma in the fourth quarter worth approximately $57,000. Banco Bilbao Vizcaya Argentaria S.A. purchased a new position in shares of Zosano Pharma in the fourth quarter worth approximately $182,000. UBS Group AG increased its position in shares of Zosano Pharma by 93.1% in the fourth quarter. UBS Group AG now owns 68,557 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 33,057 shares in the last quarter. Finally, BlackRock Inc. increased its position in shares of Zosano Pharma by 6.8% in the first quarter. BlackRock Inc. now owns 385,675 shares of the biotechnology company’s stock worth $216,000 after acquiring an additional 24,431 shares in the last quarter. 17.05% of the stock is currently owned by institutional investors.

About Zosano Pharma

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.

Featured Story: Do stock splits help investors?

Get a free copy of the Zacks research report on Zosano Pharma (ZSAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.